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CASE REPORT

Hemophagocytic Lymphohistiocytosis Secondary to
Disseminated Histoplasmosis
A Report of 3 Cases and Review of the Literature
Anastasia Wasylyshyn, MD,* Gina Maki, DO,† Kathleen A. Linder, MD,*‡ and Erica S. Herc, MD†

Abstract: Hemophagocytic lymphohistiocytosis is a syndrome of immune dysregulation that can lead to an overwhelming inflammatory state.
In this case series, we describe 3 cases in which disseminated Histoplasma
capsulatum infection caused hemophagocytic lymphohistiocytosis.
Key Words: histoplasmosis, Histoplasma capsulatum, hemophagocytic
lymphohistiocytosis, HLH, immunocompromised
(Infect Dis Clin Pract 2022;30: e1087)

H

emophagocytic lymphohistiocytosis (HLH) is a rare syndrome
of immune overactivation in which a defective cytotoxic T-cell
response leads to an uncontrolled inflammatory state.1–3 This syndrome can mimic severe sepsis and overwhelming infection but
can be triggered by any immune stimulating event, including malignancy, autoimmune disease, or infection, with cytomegalovirus and
Epstein-Barr virus being the most frequently described.2,3 Disseminated histoplasmosis is an uncommon cause of HLH; a large case
review suggests that less than 1% of cases of HLH worldwide are
due to histoplasmosis.3 Histoplasmosis associated with HLH has
been primarily reported in patients infected with HIV.4,5
In this case series, we present 3 immunocompromised patients with HLH secondary to disseminated histoplasmosis, all
without HIV infection, who presented in the fall of 2019 to two
tertiary care centers in southeastern Michigan.

CASE 1
A 68-year-old man, with psoriatic arthritis on tumor necrosis
factor (TNF)-α inhibitor therapy with golimumab presented in
mid-October with fevers and malaise that did not respond to
broad-spectrum antibiotics and a 6-day methylprednisolone dose
pack. On admission, he was febrile and ill appearing. Examination
showed bilateral pulmonary rhonchi and splenomegaly. Laboratories on admission were notable for thrombocytopenia and elevated
transaminases (Table 1). Chest x-ray demonstrated a pulmonary
infiltrate in the right lower lobe. He had progression of thrombocytopenia and transaminitis despite antibiotic treatment; workup
for atypical pulmonary infection was initiated. Bronchoscopy was
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unremarkable. β-D-Glucan was positive at 368 pg/mL, and fungal
serologies showed positive histoplasma H and M bands, with mycelial titers of 1:16 and yeast titers of 1:256. Urine and serum
Histoplasma antigens were greater than the upper limit of detection
(MiraVista Labs, Indianapolis, Ind). Bone marrow biopsy was performed given thrombocytopenia and showed hemophagocytosis;
ferritin was greater than 10,000 ng/mL and interleukin 2 (IL-2) receptor antibodies were positive at 3686 IU/mL. Bone marrow culture grew Histoplasma capsulatum. The patient was started on
intravenous liposomal amphotericin B 3 mg/kg per day and was
transitioned to itraconazole solution 200 mg twice a day at discharge; an itraconazole level checked 1 week into therapy was
4.4 μg/mL. The patient did not receive any immunosuppression
as treatment for HLH.

CASE 2
A 42-year-old woman with ankylosing spondylitis on methotrexate 10 mg weekly and infliximab 400 mg every 8 weeks presented with 5 days of fever, headaches, malaise, nausea, and
abdominal pain. On admission, she was febrile to 40°C; laboratories showed mild thrombocytopenia with elevated transaminases
and bilirubin (Table 1). Computed tomography (CT) of the abdomen was concerning for cholecystitis with choledocholithiasis;
splenomegaly was noted. Despite treatment with broad-spectrum
antibiotics for 7 days, initially piperacillin-tazobactam 4.5 g every
6 hours, followed by ertapenem 1 g daily, she had persistent fever
and worsening transaminase elevation and renal failure. She subsequently became hypoxic with altered mentation and required intubation; a CT chest showed diffuse ground-glass changes bilaterally.
Her renal injury progressed requiring hemodialysis, and she developed lactic acidosis and hemodynamic instability requiring vasopressor support. Ferritin level was 26,918 ng/mL and triglycerides
were 1409 mg/dL, which raised concern for HLH (Table 1). Liver
biopsy showed marked granulomatous inflammation with numerous intracellular organisms consistent with H. capsulatum. Bone
marrow biopsy showed hemophagocytosis, and Grocott methenamine silver (GMS) stain showed intracellular yeast forms consistent
with Histoplasma species. Patient's urine and serum histoplasma
antigen were both strongly positive (MiraVista Labs; Table 1).
The patient was treated with intravenous liposomal amphotericin
B 3 mg/kg per day for disseminated histoplasmosis, as well as
etoposide 72 mg intravenously every 3 days 2 doses, and dexamethasone with a taper for HLH. Her mental status, hemodynamics, and laboratory parameters all improved, and she eventually
had full renal recovery. She was transitioned to itraconazole solution 200 mg twice daily and ultimately discharged from the hospital with good recovery.

CASE 3
A 56-year-old woman with systemic lupus erythematosus
complicated by lupus nephritis and antiphospholipid antibody
syndrome managed with hydroxychloroquine 200 mg daily
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Liposomal
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Urine 14.91 ng/ Centrilobular
nodules and
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a day and
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cell function
BAL and fungal
upper lobe, and
followed by
200 mg daily
decreased
blood cultures:
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methylprednisolone
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for HLH

68/M Psoriatic arthritis on
golimumab
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Travel
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Alive

Alive

Outcome
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*Upper limit of quantification is 19.0 ng/mL.
AL, Alabama; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BAL, bronchoalveolar lavage; BMBx, bone marrow biopsy; Hgb, hemoglobin; IN, Indiana; MMF, mycophenolate mofetil; MTX,
methotrexate; PAS, periodic acid–Schiff; Plt, platelets; TG, triglycerides; WBC, white blood cell.
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TABLE 1. Clinical Characteristics of the Patients With Disseminated Histoplasmosis and HLH
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FIGURE 1. Histoplasma capsulatum organisms isolated from
bronchoalveolar lavage fluid. This lactophenol aniline blue stain
demonstrates the characteristic tuberculate macroconidia seen in
the mold phase.

and mycophenolate mofetil 500 mg twice a day presented in
early December with a 2-week history of high fever, fatigue,
and dry cough. On admission, she was febrile to 39.3°C and
hypoxic requiring 15 L of O2. She was pancytopenic with acute
kidney injury and elevated transaminases (Table 1). International normalized ratio (INR) was greater than 9.0. Ferritin was
14,964 ng/mL and triglycerides were elevated at 314 mg/dL. A
CT scan of the chest demonstrated centrilobular nodules and
ground-glass opacities, most prominent in the left upper lobe,
and mild mediastinal lymphadenopathy. The patient was started
on dexamethasone 20 mg daily given concern for HLH; this
was increased to methylprednisolone 1 g daily after 2 days. Bone
marrow biopsy was initially deferred because of supratherapeutic
INR. Three days later, she was started on ruxolitinib 15 mg twice a
day given lack of improvement on corticosteroids. However, she
continued to have progressive hypoxia and required intubation.
Once patient's INR had normalized, bone marrow biopsy was
performed; this demonstrated intracellular yeast, positive on
GMS and periodic acid–Schiff stains, and macrophages with
hemophagocytosis were present. The patient's serum histoplasma
antigen was greater than the upper limit of quantification, and the
histoplasma urine antigen was 14.91 ng/mL (MiraVista Labs).
Both fungal blood cultures and bronchoalveolar lavage cultures
ultimately grew H. capsulatum (Fig. 1). The patient was started
on intravenous liposomal amphotericin B at a dose of 3 mg/kg
per day but continued to have worsening respiratory and renal
function. She required initiation of hemodialysis. Eight days after
admission, in the face of worsening hypoxia and increasing vasopressor requirements, her family decided to withdraw care and
the patient died.

DISCUSSION
When reviewed together, these 3 cases illustrate a broad range
of clinical presentations associated with secondary HLH caused by
disseminated histoplasmosis. In all 3 cases, an immunocompromised patient presented with a nonspecific syndrome of fevers,
malaise, and respiratory symptoms. Diagnosis of HLH was made
early in the patients' clinical courses, but awareness of histoplasmosis as the inciting event happened later in the clinical course.
The pathophysiology of HLH is related to excessive immune
stimulation and dysregulation. Typically, antigens are presented to
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

HLH Due to Histoplasmosis

cytotoxic T cells and natural killer (NK) cells, leading to the production of perforins, triggering cell lysis.2,3 This exerts negative
feedback and dampens the subsequent immune response.1,6 In
HLH, defective cytotoxic T and NK cells do not exert negative
feedback, leading to uncontrolled immune activation and aberrant
activity.2 Unlike primary HLH in which the negative feedback response to cytotoxic T cell and NK cells is impaired because of genetic defects, the mechanism of secondary HLH varies depending
on the etiology. The NK cells are thought to be particularly relevant
for HLH triggered by infection, as NK cells conduct surveillance to
remove activated cytotoxic T cells and infected macrophages.6
The exact mechanism as to how histoplasmosis triggers HLH
is unclear. However, defense against Histoplasma is mediated by
T cells and activated macrophages.7,8 Macrophages phagocytose
Histoplasma yeast forms and eventually triggers a T helper 1
cell–mediated immune response that leads to the release of cytokines
including interferon γ and TNF-α, which are integral to granuloma
formation.7 Other intracellular pathogens that cause granuloma formation like M. tuberculosis, leishmaniasis, and Rickettsia infection
have also been implicated in causing HLH.3,9 Hemophagocytic
lymphohistiocytosis could be caused by either excessive antigen
presentation or excessive cytokine release as part of an aberrant
response to disseminated histoplasmosis.
One might expect that patients with a healthy immune system would be more likely to develop HLH, because they may have
a stronger cytokine response. However, in cases where histoplasmosis is the triggering agent of HLH, patients are often heavily
immunosuppressed, suggesting that HLH is more related to immune dysregulation rather than immune activation.5,6 Most reported cases of histoplasmosis-associated HLH are in the setting
of HIV with depressed CD4 cell count.4–6,10,11 In our series, 2
of the patients were on TNF-α inhibitors for autoimmune disease,
which would presumably blunt cytokine release, and the third was
broadly immunosuppressed. Tumor necrosis factor α inhibitors
are a well-described risk factor for histoplasmosis.12 Another series
noted a high rate of TNF-α inhibitor use in patients who developed
HLH secondary to infection, even those infections not significantly
modulated by granuloma formation.9 Perhaps the impairment of
the granulomatous response in some patients on TNF-α inhibitors
contributes to loss of negative feedback and triggers HLH.
Clinical manifestations of HLH may be subtle and can include
fever, fatigue, and splenomegaly (Table 2).13,14 Laboratory investigation may demonstrate pancytopenia, elevated triglycerides,
significantly elevated ferritin, low NK cell activity, and elevated
TABLE 2. Clinical and Laboratory Criteria for the Diagnosis* of
HLH
1. Fever >38.5°C
2. Splenomegaly
3. Cytopenia with at least 2 of the following:
Hemoglobin <9.0 g/dL
Platelets <100  109 cells/L
Absolute neutrophil count <1.0  109 cells/uL
4. Hypertriglyceridemia
Fasting triglycerides ≥265 mg/dL
Hyperfibrinogenemia (fibrinogen ≤150 mg/dL)
5. Hemophagocytosis in bone marrow, spleen, lymph node, or liver
6. Low or absent NK cell activity
7. Ferritin ≥500 ug/L
8. Elevated soluble CD25 (soluble IL-2 receptor α) ≥ 2400 U/mL
*Diagnosis requires fulfillment of 5 criteria.
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soluble CD25 (soluble IL-2 receptor α).13,14 If left untreated, HLH
can rapidly progress to hemodynamic instability and multiorgan
failure. The clinical manifestations of HLH are similar to sepsis
and can be difficult to recognize clinically, especially in the setting
of infection as trigger for HLH. Prompt identification and treatment
are warranted to minimize morbidity and mortality.
The current recommended therapy for HLH, HLH-2004,
involves chemo-immunotherapy and subsequent hematopoietic
stem cell transplantation.13,14 However, the original treatment
guideline draws from data on primary HLH, which may not apply
to all patients.13,14 There are currently no evidence-based treatment recommendations for HLH related to an infectious process,
and the widely accepted HLH-2004 guidelines do not have a
strong recommendation for how to balance treating an underlying
infection with suppression of the overwhelming immune response.
The American Society of Hematology encourages use of the full
HLH-2004 chemotherapy protocol in the setting of viral infections,
specifically Epstein-Barr virus and HIV, but acknowledge that HLH
induced by intracellular infections may respond to directed antimicrobial therapy.4,11,15 This alludes to the importance of a rigorous
infectious workup when managing adults with HLH. This includes
not only testing for viral infections but also workup for histoplasmosis in the appropriate geographical location. In our case series, all 3
patients lived in Michigan, where histoplasmosis is endemic; 2 had
notable outdoor exposures. Physicians caring for patients with HLH
should elicit pertinent travel and exposure histories and consider
whether a patient has resided in an area considered to be endemic
for histoplasmosis.8,16 In addition, changing patterns of human land
use and possibly climate change may lead to expansion of the area
in which Histoplasma is considered to be endemic, and physicians
outside the classic range will need to be aware of the association between HLH and histoplasmosis.17
Given the lack of clear guidance on management of HLH related to underlying infection, it is not surprising that our 3 cases were
all managed differently. One patient improved with antifungal therapy
alone, 1 received steroids prior to identification of histoplasmosis and
subsequently died, and 1 received concomitant antifungal therapy as
well as full HLH-2004 protocol (dexamethasone and etoposide) with
improvement. Our experience adds weight to the theory that some
cases of HLH secondary to histoplasmosis can be managed with
treatment of the underlying infection alone and without HLH-2004
protocol chemotherapy.4,6,11 More study is needed to determine
which patients with HLH triggered by histoplasmosis are likely
to improve with antimicrobial therapy alone as opposed to those
who require additional immunosuppressive therapy.
It is known that secondary HLH can be triggered by underlying infection, most commonly viral infections. However, it is imperative to consider histoplasmosis as an infectious trigger of
HLH, particularly in patients who are immunocompromised and
who live in an endemic area, which our case series illustrates.
As HLH is a condition with a high rate of morbidity and mortality,
it requires prompt recognition. If histoplasmosis is identified early
as a cause of secondary HLH, early initiation of active antifungals
can be lifesaving and may prevent the need for further administration of immunosuppressive chemotherapy.
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